Skip to main content
  • Register
  • Help
  • Contact us

BAT to invest £126m in Organigram as it expands 'beyond nicotine'

Thu 11 March 2021 12:00 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - British American Tobacco said on Thursday that it will invest around £126m for a 19.9% stake in Canada's Organigram, a company focused on research and product development activities of next generation adult cannabis products, as it looks to expand its portfolio "beyond nicotine".

Through the collaboration, BAT said it will gain access to cutting-edge R&D technologies, product innovation and cannabis expertise, complementing its "extensive plant-based expertise and development capabilities".

"Organigram has a proven track record of consumer-led innovation and developing high quality adult-use recreational and medical cannabis products, which are legally available in Canada," BAT said. "By leveraging Organigram's first-hand experience, BAT will deepen its understanding of this rapidly expanding and evolving area."

BAT's investment will make it Organigram's largest shareholder and give the company the ability to appoint two directors to the board directors and allow representation on its investment committee.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast